LuciBinim — Binimetinib 15 mg, 180 pcs, Lucius

LuciBinim — Binimetinib Tablets 15 mg, 180 Tablets

Product code: 503

93870₴ 102318₴ -8% On order · from 10 days

Analogues

Binixen LuciBinim
1
Active ingredient
Dosage form Tablets
Tablets per pack 180

LuciBinim is an advanced targeted antineoplastic agent belonging to the MEK kinase inhibitor class, indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation, as well as other solid tumors in combination with BRAF inhibitors. The active pharmaceutical ingredient is binimetinib at a strength of 15 mg supplied as film-coated oral tablets (Binimetinib Tablets 15 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Binimetinib is a highly selective oral allosteric inhibitor of MEK1 and MEK2 kinases (mitogen-activated protein kinase kinase), which are components of the MAPK/ERK signaling pathway playing a crucial role in tumor cell proliferation, survival, and metastasis. In patients with tumors harboring BRAF mutations (such as V600E or V600K), the ERK signaling pathway is constitutively hyperactivated. Combining a MEK inhibitor (binimetinib) with a BRAF inhibitor (such as encorafenib) effectively blocks this pathway, overcoming or delaying resistance and achieving robust antitumor activity.

Supplied in a package containing 180 tablets of 15 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciBinim 15 mg:

  • ✅ Selective MEK1/2 Inhibition: Targeted blockade of kinases within the MAPK/ERK signaling pathway.
  • ✅ Synergistic Combination: High therapeutic efficacy when co-administered with BRAF inhibitors in mutant melanoma.
  • ✅ Proven Clinical Efficacy: Prolongation of progression-free survival and overall survival in patients.
  • ✅ Convenient Oral Dosing: Taken orally twice daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Mektovi).

LuciBinim is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Binimetinib — 15 mg.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal anhydrous silica. Coating: hypromellose, titanium dioxide, macrogol, colorants.

Packaging and Presentation: Film-coated tablets, 15 mg strength. Each package contains 180 tablets along with prescribing information. Labeled with LuciBinim (Binimetinib Tablets 15 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Binimetinib is a reversible allosteric inhibitor of MEK1 and MEK2 kinases. MEK proteins are upstream regulators of ERK kinase, which stimulates cell growth and proliferation. Mutations in the BRAF gene (e.g., V600E) lead to chronic activation of the MAPK/ERK pathway. Binimetinib inhibits MEK activation by BRAF kinases and blocks MEK kinase activity itself, resulting in the suppression of tumor cell proliferation.

Pharmacokinetics:

  • Absorption: Following oral administration, binimetinib is rapidly absorbed; peak plasma concentration (Tmax) is achieved within approximately 1.5 to 2 hours. Absolute bioavailability is approximately 96%. Food intake has no clinically significant effect on overall exposure.
  • Distribution: Human plasma protein binding is approximately 97.4%.
  • Metabolism: Extensively metabolized in the liver, primarily via glucuronidation (mediated by UGT1A1), as well as CYP-mediated oxidation and N-dealkylation.
  • Elimination: Excreted predominantly via feces (approx. 62% as metabolites) and renally (approx. 32%). Terminal elimination half-life (T1/2) averages approximately 3.5 to 7 hours.

LuciBinim is indicated in adult patients for:

  • Melanoma: In combination with a BRAF inhibitor (e.g., encorafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (V600E or V600K).

LuciBinim is administered orally twice daily every day (approximately every 12 hours).

Dosing Regimen:
The recommended standard dose of binimetinib in combination with encorafenib is 45 mg (three 15 mg tablets) twice daily (total daily dose of 90 mg).

Administration Guidelines:
Tablets can be taken regardless of food intake with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses to make up for a missed dose).

Administration of LuciBinim is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to binimetinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction.

Binimetinib is metabolized primarily via glucuronidation by UGT1A1 and to a lesser extent by CYP enzymes:

  • Strong UGT1A1 or CYP Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): May decrease binimetinib plasma concentrations and reduce efficacy (avoid concurrent use).
  • UGT1A1 Inhibitors: May increase systemic binimetinib exposure.
  • Transporter Substrates: Binimetinib is a weak inhibitor or substrate of certain transporters, though clinically significant interactions with most co-administered medications are absent.

Pregnancy:
LuciBinim is contraindicated during pregnancy. Based on its mechanism of action, binimetinib may cause fetal harm and embryotoxicity when administered to pregnant women. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 30 days following the final dose.

Lactation:
Excretion of binimetinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment and for 3 days post-therapy.

The most frequent and clinically significant adverse reactions associated with binimetinib (in combination with encorafenib) include:

  • Cardiovascular System: Left ventricular ejection fraction decrease, arterial hypertension. Baseline and periodic cardiac function monitoring required.
  • Gastrointestinal Tract: Nausea, diarrhea, vomiting, abdominal pain, constipation.
  • Dermatologic Reactions: Rash, dermatitis, hyperkeratosis, dry skin.
  • General Disorders: Fatigue, asthenia, pyrexia, arthralgia, muscle spasms (elevated blood creatine phosphokinase [CPK] levels may occur).
  • Ocular Disorders: Visual disturbances, including serous retinopathy and retinal pigment epithelial detachment.

Symptoms:
Specific acute overdose symptoms of binimetinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (gastrointestinal, dermatologic, fatigue, and laboratory abnormalities).

Treatment:
No specific antidote exists. In case of overdose, discontinue binimetinib and initiate supportive and symptomatic care under strict medical supervision.

Storage Requirements for LuciBinim 15 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciBinim 15 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Binimetinib Tablets 15 mg, and 180 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00